Presented at Abstracts reporting this study were presented at the following conferences: the American Academy of Neurology (AAN) 2022 Annual Meeting (2–7 April, Seattle, USA); and the 8th European ...

The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. This week, the medicine, first approved in 2009, was listed as discontinued on the ...

Julie Kim is set to replace Christophe Weber as the new chief executive officer of Takeda Pharmaceutical Co., becoming the first woman to lead the more than 240-year-old Japanese drugmaker.

In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited (NYSE:TAK) stands against the other Japanese stocks. As the dangers of natural disasters increase and ...

Evox Therapeutics is the second UK biotech to sign a big deal with a pharma giant this week, snaring an $882 million partnership with Takeda for up to five rare disease programmes. The alliance ...

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers ...

Takeda has bolstered its near-term pipeline in rare haematological disorders by licensing rights to a polycythaemia vera (PV) treatment being developed by Protagonist Therapeutics. The Japanese ...

Shares of Ascentage Pharma Group (AAPG) (OTCPK:AAPGV) (OTCPK:ASPHF), which is backed by Takeda (NYSE:TAK), were trading largely flat Friday following the company's $126M U.S. initial public offering.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Initially, the remains could not be identified and it wasn't until a facial reconstruction was circulated by the media that they were later confirmed as those of 60-year-old Ean Coutts.

Takeda Pharmaceuticals has named Julie Kim as the first woman to lead the 244-year-old Japanese drugmaker, a rarity in senior management in the world’s fourth-largest economy. Kim, a US citizen ...